{"id":1714,"date":"2026-07-06T22:54:16","date_gmt":"2026-07-07T02:54:16","guid":{"rendered":"https:\/\/www.insilens.com\/?p=1714"},"modified":"2026-07-06T22:56:08","modified_gmt":"2026-07-07T02:56:08","slug":"novartis-acquires-myricx-bio-next-generation-adc-payload-platform","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=1714","title":{"rendered":"Novartis Acquires Myricx Bio | Next-Generation ADC Payload Platform"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Summary<\/h4>

Novartis agreed to acquire Myricx Bio for up to $1.5 billion, including $1.1 billion upfront, to add a novel N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate payload platform and two lead ADC assets. The transaction is a major platform signal because it shows large pharma paying premium value for payload architecture, not only for late-stage clinical assets.<\/p>

What Happened<\/h4>

Novartis entered an agreement to acquire UK-based Myricx Bio, which is developing ADCs using NMTi payloads. The platform is designed to overcome limitations of common ADC payload classes, including TOPO-1 inhibitor and tubulin inhibitor payloads. Myricx has two lead ADC assets directed toward B7-H3 and HER2, with broader potential across solid tumors. The company source confirmed the structure: $1.1 billion upfront plus up to $400 million in milestones.<\/p>

Deep Analysis<\/h4>

This transaction highlights the next frontier in ADC competition: payload differentiation. The first wave of ADC value creation was target-led, focused on antigens such as HER2, TROP2, Nectin-4, CD19, CD22, and B7-H3. The next wave is increasingly about payload, linker, resistance biology, and therapeutic index. Novartis is effectively buying into a new cytotoxic payload class that could be used across multiple tumor targets. NMT biology is attractive because NMT activity supports key cancer-cell survival processes. If NMTi payloads demonstrate differentiated killing and improved tolerability, they could provide Novartis with a reusable ADC engine rather than a single-product opportunity. The deal also fits Novartis’ broader strategy of scaling platform modalities, similar to its radioligand therapy playbook.<\/p>

Related News \/ Competitive Context<\/h4>

The ADC field is experiencing intense business development activity. Gilead has expanded Trodelvy into earlier TNBC settings, Daiichi Sankyo\/AstraZeneca continue advancing DXd-based ADCs, and multiple companies are developing new payload systems to improve therapeutic index. At the same time, safety concerns around some ADCs, including lymphoma ADCs using highly potent payloads, have reminded investors that payload choice can determine commercial success or failure. Novartis\/Myricx should be viewed in that context: payload innovation is becoming a core competitive layer.<\/p>

Competitive Displacement<\/h4>

This deal pressures ADC companies relying on standard TOPO-1 or tubulin payloads, particularly if Myricx payloads show activity in resistant tumor models. It also positions Novartis to compete more credibly against Daiichi Sankyo\/AstraZeneca, Gilead, Pfizer, AbbVie, and other ADC-heavy oncology players. The acquisition is not an immediate commercial displacement event, but it gives Novartis a potentially differentiated payload backbone for future ADC franchises.<\/p>

Company \/ Product Background<\/h4>

Myricx Bio is a UK biotechnology company developing ADC payloads based on N-myristoyltransferase inhibition. NMT is an enzyme involved in lipid modification of proteins important for cancer-cell function and survival. Antibody-drug conjugates combine tumor-targeting antibodies with cytotoxic payloads through linkers, aiming to deliver potent cell-killing activity selectively to cancer cells while reducing systemic exposure.<\/p>

Signal Extraction<\/h4>

– Up to $1.5B transaction value, including $1.1B upfront.
– Validates NMTi payloads as a potentially new ADC payload class.
– Strengthens Novartis oncology and targeted drug conjugate strategy.
– Shows big pharma paying premium value for platform architecture.
– Reinforces payload differentiation as a key ADC competitive frontier.<\/p>

Insilens Take<\/h4>

The strategic signal is that ADC platform value is migrating from antigen selection alone to payload innovation. Novartis is not simply buying two preclinical\/early assets; it is buying optionality across a payload class. For Insilens, this should be tracked as a major modality signal because ADC innovation affects both solid tumor and hematologic cancer development, especially where payload resistance and therapeutic index determine whether a program can scale commercially.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Summary Novartis agreed to acquire Myricx Bio for up to $1.5 billion, including $1.1 billion upfront, to add a novel N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate payload platform and two lead ADC assets. The transaction is a major platform signal because it shows large pharma paying premium value for payload architecture, not only for late-stage clinical […]<\/p>\n","protected":false},"author":1,"featured_media":1715,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,2],"tags":[],"class_list":["post-1714","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-deals-and-financing"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1714"}],"version-history":[{"count":4,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1714\/revisions"}],"predecessor-version":[{"id":1719,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1714\/revisions\/1719"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/1715"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}